Company Overview

Forian Inc. is a data science and analytics company focused on transforming healthcare and life sciences decision-making through advanced data aggregation, analytics, and real-world evidence. The company operates primarily at the intersection of healthcare analytics, life sciences, and regulated markets, with a historical emphasis on the cannabis and emerging therapeutics sectors. Forian’s core value proposition is providing actionable insights derived from large-scale, longitudinal, and multi-source datasets to support clinical, commercial, and regulatory decisions.

The company generates revenue by licensing proprietary datasets, analytics platforms, and data-driven services to pharmaceutical companies, biotechnology firms, payers, providers, and other healthcare stakeholders. Forian’s strategic advantage lies in its ability to integrate disparate healthcare data sources, including real-world patient data, and apply advanced analytics to niche and underserved therapeutic and regulatory markets. Forian was formed through the merger of multiple healthcare data businesses and became publicly traded in 2021, positioning itself as a specialized analytics provider rather than a broad-based health IT vendor.

Business Operations

Forian’s operations are organized around data analytics and real-world evidence solutions delivered through proprietary platforms and services. The company’s primary revenue drivers include data licensing agreements, analytics subscriptions, and customized research services for life sciences and healthcare clients. Its offerings are designed to support drug development, market access strategy, patient outcomes research, and commercialization planning, particularly in complex or regulated therapeutic areas.

The company operates primarily in the United States, with analytics capabilities that support both domestic and international healthcare markets. Forian controls proprietary datasets and analytics technologies developed internally and through acquisitions, integrating claims data, electronic health records, and specialized market data. The company has expanded its capabilities through acquisitions of complementary data and analytics businesses, including Kyber Data Science, which strengthened its real-world evidence and advanced analytics offerings. Data inconclusive based on available public sources regarding material joint ventures.

Strategic Position & Investments

Forian’s strategic direction centers on expanding its role as a data intelligence partner to life sciences companies seeking evidence-based insights across the product lifecycle. Growth initiatives have focused on deepening analytics capabilities, increasing dataset breadth, and targeting biopharmaceutical clients operating in complex or emerging therapeutic categories. The company has emphasized recurring revenue through long-term data licensing and analytics contracts.

Strategically, Forian has pursued acquisitions to enhance scale and analytical sophistication, most notably Kyber Data Science, which added advanced statistical modeling and real-world evidence expertise. The company continues to invest in data integration technologies and analytics platforms designed to support regulatory-grade research and commercialization strategy. Public disclosures indicate ongoing evaluation of opportunities in adjacent healthcare analytics markets, though specific future investments are not detailed and remain data inconclusive based on available public sources.

Geographic Footprint

Forian is headquartered in the United States, with its primary operational and revenue base concentrated in the North American healthcare market. The company’s analytics platforms and datasets are used by clients with global operations, enabling indirect participation in international healthcare and life sciences markets, particularly where U.S.-based real-world evidence is relevant for regulatory or commercial planning.

While Forian does not report extensive physical operations outside the United States, its data products support decision-making across global pharmaceutical and biotechnology organizations. International revenue exposure exists through multinational clients, though the majority of reported operations and data assets are U.S.-centric.

Leadership & Governance

Forian is led by executives with backgrounds in healthcare analytics, data science, and life sciences strategy. Leadership emphasizes data-driven decision-making, disciplined capital allocation, and building scalable analytics platforms tailored to regulated healthcare markets. The governance structure reflects public company standards, with oversight focused on financial discipline, data integrity, and regulatory compliance.

Key executives include:

• Max Wygod – Executive Chairman
• Dan Lounsbury – Chief Executive Officer
• Richard Gliklich – President
• Jason O’Grady – Chief Financial Officer
• Sami Gharbi – Chief Technology Officer

The leadership team’s strategic vision centers on establishing Forian as a trusted provider of real-world evidence and advanced analytics for life sciences organizations operating in complex and evolving healthcare environments.